Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Sarah Goring"'
Autor:
Nicolas Girard, Mariam Besada, Basia Rogula, Stefano Lucherini, Lien Vo, Mohammad A. Chaudhary, Sarah Goring, Greta Lozano-Ortega, Mia Tran, Nebibe Varol, Nathalie Waser, Jay M. Lee, Jonathan Spicer
Publikováno v:
Cancers, Vol 16, Iss 13, p 2492 (2024)
Background: This study aimed to estimate the relative efficacy of neoadjuvant nivolumab in combination with chemotherapy (neoNIVO + CT) compared to relevant treatments amongst resectable non-metastatic non-small-cell lung cancer (rNSCLC) patients. Me
Externí odkaz:
https://doaj.org/article/6e19752816b0486883be861758bb2cad
Autor:
Lorne Clarke MD, Carolyn Ellaway MBBS, PhD, Helen E. Foster MD, MBBS, Roberto Giugliani MD, PhD, Cyril Goizet MD, PhD, Sarah Goring MSc, Sara Hawley MSc, Elaina Jurecki MS, RD, Zaeem Khan MPH, BSc, Christina Lampe MD, Ken Martin MD, Suzanne McMullen MHA, BSc, John J. Mitchell MD, Fathima Mubarack MSc, MHA, H. Serap Sivri MD, Martha Solano Villarreal MD, PhD, Fiona J. Stewart MB, BS, Anna Tylki-Szymanska MD, PhD, Klane White MD, MSc, Frits Wijburg MD, PhD
Publikováno v:
Journal of Inborn Errors of Metabolism and Screening, Vol 7 (2018)
As therapies are developed for rare disorders, challenges of early diagnosis become particularly relevant. This article focuses on clinical recognition of mucopolysaccharidoses (MPS), a group of rare genetic diseases related to abnormalities in lysos
Externí odkaz:
https://doaj.org/article/77e2c55a1f004dacb060921ca52b1269
Autor:
Zarmina S Khankhel, Sarah Goring, Sarah Bobiak, Francois-Xavier Lamy, Dweeti Nayak, Jamie Garside, Emily S Reese, Nancy Schoenherr
Publikováno v:
Future Oncology. 18:2321-2338
Background: A systematic review was conducted to understand clinical, economic and health-related quality-of-life outcomes in second-line biliary tract cancer. Materials & methods: The review followed established recommendations. The feasibility of n
Autor:
Sarah Goring, Jennifer Horton
Publikováno v:
Canadian Journal of Health Technologies. 2
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a disorder caused by a genetic mutation, and is characterized by hematologic and autoinflammatory symptoms that are severe and progressive. It is typically seen in older men
Autor:
Sarah Goring, Quenby Mahood
Publikováno v:
Canadian Journal of Health Technologies. 2
Evidence of radioiodine resensitization was reported in 4 single-arm clinical trials and 3 uncontrolled retrospective cohort studies, which included between 3 and 20 patients. Over half of patients in these 7 studies demonstrated increased radioiodin
Autor:
Sarah Goring, Nebibe Varol, Nathalie Waser, Evan Popoff, Greta Lozano-Ortega, Adam Lee, Yong Yuan, Laura Eccles, Phuong Tran, John R. Penrod
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 170
The study objective was to estimate the relationship between objective response and survival-based endpoints by drug class, in first-line advanced non-small cell lung cancer (aNSCLC).A systematic literature review identified randomized controlled tri
Publikováno v:
Future oncology (London, England). 18(12)
Aim: The aim of this systematic literature review was to describe treatment patterns in nonmetastatic non-small-cell lung cancer. Methods: A search was conducted in MEDLINE and EMBASE. Eligible studies were multicentered (>50 patients) and conducted
Autor:
Sarah Goring, Lory Picheca
Publikováno v:
Canadian Journal of Health Technologies. 2
One relevant systematic review and network meta-analysis (which included 1 relevant randomized controlled trial), 4 non-randomized studies, and 6 evidence-based guideline reports, representing 5 evidence-based guidelines were identified in this repor
Autor:
Paul J Bröckelmann, Mehul Dalal, Timothy M Illidge, Dirk Huebner, Kerstin Mueller, Suzanne McMullen, Ashish Gautam, Erin Zagadailov, J Ben Wilson, Aspasia Stamatoullas, Sarah Goring
Publikováno v:
British Journal of Haematology
Bröckelmann, P J, Mcmullen, S, Wilson, J B, Mueller, K, Goring, S, Stamatoullas, A, Zagadailov, E, Gautam, A, Huebner, D, Dalal, M & Illidge, T 2019, ' Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom ', British Journal of Haematology, vol. 184, no. 2, pp. 202-214 . https://doi.org/10.1111/bjh.15566
Bröckelmann, P J, Mcmullen, S, Wilson, J B, Mueller, K, Goring, S, Stamatoullas, A, Zagadailov, E, Gautam, A, Huebner, D, Dalal, M & Illidge, T 2019, ' Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom ', British Journal of Haematology, vol. 184, no. 2, pp. 202-214 . https://doi.org/10.1111/bjh.15566
Summary First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPP escalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, pr
Publikováno v:
Journal of comparative effectiveness research. 9(2)
Aim: To determine the effectiveness of nivolumab compared with routine clinical practice (RCP) for patients with gastric or gastroesophageal cancer refractory to, or intolerant of, two or more previous regimens, using real-world electronic patient re